Clinical Trial Update: Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069 [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated the relative bioavailability of up to five formulations of AZD5069 in individuals with uncontrolled and persistent asthma and has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• AZD5069 (CXCR2 inhibitor)

Snippet

Sponsor: AstraZeneca | Conditions: Uncontrolled and Persistent Asthma | Phase 1 | Status: COMPLETED